The Mouse CD272 Monoclonal Antibody (PK18-6) is a specialized tool for researchers interested in studying CD272, a key immune regulatory protein. This monoclonal antibody, designated as AGEL0133, is carefully developed to target the CD272 protein in mouse samples, making it a valuable asset for immunology and cancer research applications.CD272, also known as B- and T-lymphocyte attenuator (BTLA), is a crucial checkpoint molecule that modulates immune responses by inhibiting lymphocyte activation and proliferation. By specifically recognizing and binding to CD272, this monoclonal antibody allows for precise detection and analysis of CD272 expression in various cell types.
This capability is essential for investigating the role of CD272 in immune regulation and understanding its implications in diseases such as cancer, autoimmune disorders, and inflammatory conditions.Researchers leveraging the Mouse CD272 Monoclonal Antibody (PK18-6) can delve into the intricate mechanisms of immune regulation mediated by CD272, paving the way for potential therapeutic interventions targeting this pathway. With its reliable performance and validated compatibility for various experimental techniques, this antibody serves as a critical tool for unraveling the complex interplay of CD272 in immune responses and disease pathology.
Product Title:
Purified Anti-Mouse CD272 Antibody [PK18.6]
SKU:
AGEL0133
Size:
25µg, 100µg
Clone No:
PK18.6
Synonyms:
B- and T-lymphocyte attenuator;Btla;B- and T-lymphocyte-associated protein;CD272;Btla;
Host Species:
Rat
Reactivity:
Mouse
Application:
FCM
Isotype:
Rat IgG1, κ
Isotype Control:
Purified Rat IgG1, κ Isotype Control[HRPN]
Form:
Liquid
Conjugation:
Unconjugated
Recommended Use:
Each lot of this antibody is quality control tested by flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase.
Background:
CD272, also known as B and T lymphocyte attenuator (BTLA), is an Ig superfamily co-inhitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand herpes virus entry mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significantly higher expression of BTLA compared with effectors and naïve T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It was reported that BTLA may regulate T cell function by binding to B7-H4, but further studies are needed to confirm. The existence of three distinct BTLA alleles has been reported.